Technology Addresses Secretion Bottlenecks in Recombinant Protein Expression
Geneva, Switzerland (PRWEB) April 17, 2013 – Selexis SA, a serial innovation company focused on drug discovery for lead identification, cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the launch of its novel platform, SURE CHO-Mplus™ Libraries, which were designed and constructed to address a broad range of issues surrounding recombinant protein secretion including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications.
With certain recombinant proteins, optimal expression cannot be achieved by elevated transcription alone. Low productivity can be the result of a myriad of issues including faulty cleavage and protein precipitation, improper folding, metabolic overload, or backlog in protein translocation or vesicle trafficking. Within each of the Company’s SURE CHO-Mplus™ Libraries, between 8-12 secretory components have been modified to address specific secretion bottlenecks, such as aberrant glycosylation or improper protein folding. The SURE CHO-Mplus™ Libraries have been shown to significantly improve production levels of a broad range of proteins including difficult-to-express monoclonal antibodies, enzymes, structural proteins and fusion proteins such as Fc-fusions and minibodies.
“The Selexis SURE CHO-Mplus™ Libraries are a novel and powerful advancement in biologic protein expression. Selexis’ libraries enable a multiplex approach to determine optimal secretory configurations for recombinant proteins,” said Dr. Igor Fisch, CEO, Selexis SA. “With the Selexis SURE CHO-Mplus™ Libraries, biopharmaceutical companies now have solutions for optimizing the commercial viability of biologic development programs including target expression campaigns that would be otherwise terminated because of protein secretion issues.”
The CHO-Mplus™ Libraries that address secretion bottlenecks include: